WO2011132008A3 - Controlled release pharmaceutical composition - Google Patents

Controlled release pharmaceutical composition Download PDF

Info

Publication number
WO2011132008A3
WO2011132008A3 PCT/HU2011/000037 HU2011000037W WO2011132008A3 WO 2011132008 A3 WO2011132008 A3 WO 2011132008A3 HU 2011000037 W HU2011000037 W HU 2011000037W WO 2011132008 A3 WO2011132008 A3 WO 2011132008A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
release pharmaceutical
controlled release
sustained release
tablet
Prior art date
Application number
PCT/HU2011/000037
Other languages
French (fr)
Other versions
WO2011132008A2 (en
Inventor
Tibor KORBÉLY
Zsolt Zsigmond
György UJFALUSSY
Zoltánné PÁLFI
Zoltán Horváth
Ádám ORBÁN
Krisztina ÁBRAHÁM
Zsolt Istavánné BOKOR
Original Assignee
EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU1000224A external-priority patent/HU1000224D0/en
Priority claimed from HU1100207A external-priority patent/HU230983B1/en
Application filed by EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság filed Critical EGIS Gyűgyszergyár Nyilvánosan Múködő Részvény társaság
Publication of WO2011132008A2 publication Critical patent/WO2011132008A2/en
Publication of WO2011132008A3 publication Critical patent/WO2011132008A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to a sustained release pharmaceutical composition. Particularly, a sustained release compressed tablet which contains coated compacted granules containing the active ingredient quetiapine and further excipients. If desired, one or more coatings are on the surface of the tablet.
PCT/HU2011/000037 2010-04-22 2011-04-21 Controlled release pharmaceutical composition WO2011132008A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
HUP1000224 2010-04-22
HU1000224A HU1000224D0 (en) 2010-04-22 2010-04-22 Pharmaceutical composition of controlled release
HU1100207A HU230983B1 (en) 2011-04-19 2011-04-19 Modified release composition
HUP1100207 2011-04-19

Publications (2)

Publication Number Publication Date
WO2011132008A2 WO2011132008A2 (en) 2011-10-27
WO2011132008A3 true WO2011132008A3 (en) 2012-03-15

Family

ID=89990254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2011/000037 WO2011132008A2 (en) 2010-04-22 2011-04-21 Controlled release pharmaceutical composition

Country Status (1)

Country Link
WO (1) WO2011132008A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078435A1 (en) 2012-11-14 2014-05-22 W. R. Grace & Co.-Conn. Compositions containing a biologically active material and a non-ordered inorganic oxide

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007086079A2 (en) * 2006-01-25 2007-08-02 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
WO2008012346A1 (en) * 2006-07-28 2008-01-31 Farmaprojects, S. A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
WO2009004480A2 (en) * 2007-05-07 2009-01-08 Actavis Group Ptc Ehf Quetiapine salts and their polymorphs
EP2153834A2 (en) * 2008-08-07 2010-02-17 Farmaprojects, S.A. Extended release pharmaceutical compositions comprising quetiapine salts
WO2010082220A2 (en) * 2009-01-05 2010-07-22 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
PE57198A1 (en) 1996-03-25 1998-10-10 American Home Prod PROLONGED RELEASE FORMULA
GB9611328D0 (en) 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
WO2005041935A1 (en) 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
PT103884A (en) 2006-11-17 2008-05-19 Astrazeneca Ab PROLONGED RELEASE COMPOSITIONS AND METHODS FOR THEIR PREPARATION
US20100056493A1 (en) 2007-01-25 2010-03-04 Rajesh Jain Modified release pharmaceutical composition and a process of making the same
WO2008110337A2 (en) 2007-03-09 2008-09-18 Synthon B.V. Pharmaceutical composition of quetiapine fumarate
US20110052648A1 (en) 2008-03-12 2011-03-03 Avi Avramoff Oral modified-release formulations containing thiazepines

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007086079A2 (en) * 2006-01-25 2007-08-02 Astron Research Limited Sustained release dosage form of phenothiazine derivatives containing channelizer
WO2008012346A1 (en) * 2006-07-28 2008-01-31 Farmaprojects, S. A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
WO2009004480A2 (en) * 2007-05-07 2009-01-08 Actavis Group Ptc Ehf Quetiapine salts and their polymorphs
EP2153834A2 (en) * 2008-08-07 2010-02-17 Farmaprojects, S.A. Extended release pharmaceutical compositions comprising quetiapine salts
WO2010082220A2 (en) * 2009-01-05 2010-07-22 Torrent Pharmaceuticals Limited Sustained release pharmaceutical composition of quetiapine and process for preparation thereof

Also Published As

Publication number Publication date
WO2011132008A2 (en) 2011-10-27

Similar Documents

Publication Publication Date Title
WO2009117130A3 (en) Extended release forumulation containing a wax
WO2011017108A3 (en) Cyclopropyl modulators of p2y12 receptor
WO2011076749A3 (en) Solid pharmaceutical dosage form of ticagrelor
WO2010017821A8 (en) Coated tablets with a remaining degradation surface over the time
HK1172845A1 (en) Novel pharmaceutical formulations against drug misuse
LT2808325T (en) Substituted azoles, anti-viral active ingredient, pharmaceutical composition, method for the production and use thereof
EP2220081A4 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
WO2012007729A3 (en) Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators
WO2011002857A3 (en) 3-cyanoquinoline tablet formulations and uses thereof
WO2012022919A3 (en) Nalbuphine-based formulations and uses thereof
WO2011120904A3 (en) A fast dissolving pharmaceutical composition
WO2006116349A3 (en) Sustained release formulation and dosing schedules of leukotriene synthesis inhibitor for human therapy
WO2010144477A3 (en) Sulfonylurea modulators of endothelin receptor
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2011077239A3 (en) Slow release pharmaceutical compositions of iloperidone
WO2011120903A3 (en) A fast dissolving pharmaceutical composition
WO2010115125A3 (en) Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl]-benzamide
WO2009152167A3 (en) Delivery of therapeutics
WO2011135580A3 (en) Pharmaceutical compositions of sirolimus
WO2009100886A3 (en) Formulations of flibanserin
WO2011064797A3 (en) Controlled release pharmaceutical compositions of galantamine
WO2009060064A3 (en) Pharmaceutical formulations for the oral administration of ppi
WO2010137040A3 (en) Novel pharmaceutical compositions of ranolazine
MX2011006721A (en) Pharmaceutical formulation of nanonised fenofibrate.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11727753

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11727753

Country of ref document: EP

Kind code of ref document: A2